ONCORELIEF’s Pilot Study, by University Medical Center Mainz, Germany


The International Agency for Research on Cancer estimated that the number of new cancer cases and cancer deaths worldwide in 2020 will be about 19.3 million and 9.96 million, respectively - and trends are rising.


Despite the rising cancer incidence, improvements in early detection and treatment have improved cancer survival. As a consequence, the number of cancer survivors is increasing globally, creating the need to improve not only treatment but also wellbeing and follow‐up care.


Cancer treatment often involves combined modalities such as surgery, chemotherapy, and radiotherapy. In the past decades, more effective and targeted therapeutic modalities and less destructive cancer treatments have been developed such as immunotherapy and targeted therapy.


Nevertheless, cancer and its treatment have important physical and psychosocial sequelae.


Cancer treatment encompasses not only primary treatment but also follow‐up care and management of long-term and late effects such as secondary effects and complications. Prolonged fatigue, cognitive limitations, depression/anxiety, sleep problems, pain, and sexual dysfunction are consistently present in cancer patients during and after primary treatment.


A serious oversight often negatively affecting patients’ quality of life, adherence to treatment, or even medical outcomes, is the neglect of the psychosocial side-effects of cancer on patients.


ONCORELIEF aims to develop intelligent healthcare services and tools for the post-treatment cancer patients using patient reported outcome measures (PROMs) and patient reported experience measures (PREMs) and other measurable parameters in order to promote healthy living and increased wellbeing, to provide suggestions on mental and physical health and to assist patients in performing everyday tasks.


The University Medical Center Mainz (UM Mainz), Germany together with IRST IRCCS, Meldola, Italy is preparing the pilot study to assess the functionalities of the Oncorelief System (GA App, Device Ecosyxstem, Quality of Life Index, AI Engine) and its ability and effects on patients QoL and overall health status.


It will be a multicenter study and patients will be enrolled at IRST, Italy, and at UM Mainz, Germany.


The main aim of this study will be to assess the feasibility of ONCORELIEF system in a real-life setting of AML and CRC patients. We will evaluate the Patient and healthcare professional (HCP) satisfaction with regard to the ONCORELIEF System, as well as the engagement of patients with ONCORELIEF system. The medical partner further plan to assess the impact of ONCORELIEF system on patients Quality of Life and the impact of ONCORELIEF on patients well-being measured through the the newly developed "Oncorelief Index".